{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:23Z","timestamp":1790312423037,"version":"4.1.0"},"reference-count":42,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15863","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:28:22Z","timestamp":1789468102000},"page":"1-14","source":"Crossref","is-referenced-by-count":0,"title":["Integrated analysis identified MARK4 as a prognostic and immunomodulatory biomarker in oral squamous cell carcinoma"],"prefix":"10.3892","volume":"32","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pediatric Dentistry, Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin 300041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dentistry, Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin 300041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dentistry, Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin 300041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dentistry, Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin 300041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"key20260925073129_b1-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"229","DOI":"10.12688\/f1000research.22941.1","article-title":"Oral squamous cell carcinoma: Metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis","volume":"9","author":"Bugshan","year":"2020","journal-title":"F1000Res"},{"key":"key20260925073129_b2-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.3390\/curroncol30040283","article-title":"Oral squamous cell carcinoma and concomitant primary tumors, What Do We Know? A review of the literature","volume":"30","author":"Badwelan","year":"2023","journal-title":"Curr Oncol"},{"key":"key20260925073129_b3-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"key20260925073129_b4-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.3390\/ijms24129874","article-title":"The role of IL-17 in the pathogenesis of oral squamous cell carcinoma","volume":"24","author":"Ladjevac","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260925073129_b5-ol-32-5-15863","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"key20260925073129_b6-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41368-023-00249-w","article-title":"Oral squamous cell carcinomas: State of the field and emerging directions","volume":"15","author":"Tan","year":"2023","journal-title":"Int J Oral Sci"},{"key":"key20260925073129_b7-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12903-019-0760-2","article-title":"Health-related quality of life: A retrospective study on local vs. microvascular reconstruction in patients with oral cancer","volume":"19","author":"Meier","year":"2019","journal-title":"BMC Oral Health"},{"key":"key20260925073129_b8-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jcms.2017.01.033","article-title":"Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: A review of the literature","volume":"45","author":"Blatt","year":"2017","journal-title":"J Craniomaxillofac Surg"},{"key":"key20260925073129_b9-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.32604\/or.2024.052120","article-title":"Novel insights on oral squamous cell carcinoma management using long non-coding RNAs","volume":"32","author":"Sur","year":"2024","journal-title":"Oncol Res"},{"key":"key20260925073129_b10-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41598-023-28550-y","article-title":"A circulating microRNA panel as a novel dynamic monitor for oral squamous cell carcinoma","volume":"13","author":"Piao","year":"2023","journal-title":"Sci Rep"},{"key":"key20260925073129_b11-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"British J Pharmacology"},{"key":"key20260925073129_b12-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: From basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"key20260925073129_b13-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"119646","DOI":"10.1016\/j.bbamcr.2023.119646","article-title":"Protein kinase D1-A targetable mediator of pancreatic cancer development","volume":"1871","author":"Fleming Martinez","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"key20260925073129_b14-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3390\/ijms18122543","article-title":"Protein kinase targets in breast cancer","volume":"18","author":"Garc\u00eda-Aranda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"key20260925073129_b15-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pharmtox-022420-112134","article-title":"Drugs that regulate local cell signaling: AKAP targeting as a therapeutic option","volume":"61","author":"Bucko","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key20260925073129_b16-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1042\/BCJ20230352","article-title":"Protein kinase A and local signaling in cancer","volume":"481","author":"Rosenthal","year":"2024","journal-title":"Biochem J"},{"key":"key20260925073129_b17-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"101771","DOI":"10.1016\/j.molmet.2023.101771","article-title":"Metabolic protein kinase signalling in neuroblastoma","volume":"75","author":"Smiles","year":"2023","journal-title":"Mol Metab"},{"key":"key20260925073129_b18-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s11689-024-09525-0","article-title":"Protein Kinase A in neurological disorders","volume":"16","author":"Glebov-McCloud","year":"2024","journal-title":"J Neurodevelop Disord"},{"key":"key20260925073129_b19-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1161\/CIRCULATIONAHA.112.127514","article-title":"Protein Kinase C-\u03b2 contributes to impaired endothelial insulin signaling in humans with diabetes mellitus","volume":"127","author":"Tabit","year":"2013","journal-title":"Circulation"},{"key":"key20260925073129_b20-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"110434","DOI":"10.1016\/j.cellsig.2022.110434","article-title":"Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy","volume":"99","author":"Anwar","year":"2022","journal-title":"Cell Signal"},{"key":"key20260925073129_b21-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/jcb.30468","article-title":"Therapeutic targeting of microtubule affinity-regulating kinase 4 in cancer and neurodegenerative diseases","volume":"124","author":"Alam","year":"2023","journal-title":"J Cell Biochem"},{"key":"key20260925073129_b22-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-021-03573-5","article-title":"MARK4 controls ischaemic heart failure through microtubule detyrosination","volume":"594","author":"Yu","year":"2021","journal-title":"Nature"},{"key":"key20260925073129_b23-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"15986","DOI":"10.1038\/ncomms15986","article-title":"MARK4 regulates NLRP3 positioning and inflammasome activation through a microtubule-dependent mechanism","volume":"8","author":"Li","year":"2017","journal-title":"Nat Commun"},{"key":"key20260925073129_b24-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2174\/0115672050358397250126151707","article-title":"Tauopathy in AD: Therapeutic potential of MARK-4","volume":"21","author":"Mumtaz Ahmed","year":"2024","journal-title":"Curr Alzheimer Res"},{"key":"key20260925073129_b25-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"420","DOI":"10.15252\/embr.201642455","article-title":"MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells","volume":"18","author":"Heidary Arash","year":"2017","journal-title":"EMBO Rep"},{"key":"key20260925073129_b26-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"570","DOI":"10.15252\/embr.201540970","article-title":"miR-515-5p controls cancer cell migration throughMARK4 regulation","volume":"17","author":"Pardo","year":"2016","journal-title":"EMBO Rep"},{"key":"key20260925073129_b27-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1155\/2011\/206756","article-title":"Differential signature of the centrosomal MARK4 isoforms in glioma","volume":"34","author":"Magnani","year":"2011","journal-title":"Anal Cell Pathol (Amst)"},{"key":"key20260925073129_b28-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/07391102.2020.1738959","article-title":"Impact of glioblastoma multiforme associated mutations on the structure and function of MAP\/microtubule affinity regulating kinase 4","volume":"39","author":"Naqvi","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"key20260925073129_b29-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1039\/C3MB70591A","article-title":"The structural analysis of MARK4 and the exploration of specific inhibitors for the MARK family: A computational approach to obstruct the role of MARK4 in prostate cancer progression","volume":"10","author":"Jenardhanan","year":"2014","journal-title":"Mol BioSyst"},{"key":"key20260925073129_b30-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/jcb.30022","article-title":"Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases","volume":"122","author":"Anwar","year":"2021","journal-title":"J Cell Biochem"},{"key":"key20260925073129_b31-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"22759","DOI":"10.1021\/acsomega.0c01703","article-title":"Design and development of Small-molecule Arylaldoxime\/5-Nitroimidazole hybrids as potent inhibitors of MARK4: A promising approach for Target-based cancer therapy","volume":"5","author":"Peerzada","year":"2020","journal-title":"ACS Omega"},{"key":"key20260925073129_b32-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"25945","DOI":"10.1021\/acsomega.4c00661","article-title":"Vanillin-Isatin Hybrid-induced MARK4 inhibition as a promising therapeutic strategy against hepatocellular carcinoma","volume":"9","author":"Ahmed","year":"2024","journal-title":"ACS Omega"},{"key":"key20260925073129_b33-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.apsb.2019.09.004","article-title":"PCC0208017, a novel small-molecule inhibitor of MARK3\/MARK4, suppresses glioma progression in vitro and in vivo","volume":"10","author":"Li","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"key20260925073129_b34-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20260925073129_b35-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.tibs.2009.03.008","article-title":"The tau of MARK: A polarized view of the cytoskeleton","volume":"34","author":"Matenia","year":"2009","journal-title":"Trends Biochem Sci"},{"key":"key20260925073129_b36-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/cm.21748","article-title":"Microtubule-associated proteins and enzymes modifying tubulin","volume":"80","author":"Peng","year":"2023","journal-title":"Cytoskeleton (Hoboken)"},{"key":"key20260925073129_b37-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejcb.2014.07.004","article-title":"Microtubule-associated protein\/microtubule affinity-regulating kinase 4 (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics","volume":"93","author":"Rovina","year":"2014","journal-title":"Eur J Cell Biol"},{"key":"key20260925073129_b38-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"155471","DOI":"10.1016\/j.prp.2024.155471","article-title":"MARK4 promotes the malignant phenotype of gastric cancer through the MAPK\/ERK signaling pathway","volume":"261","author":"Ma","year":"2024","journal-title":"Pathol Res Pract"},{"key":"key20260925073129_b39-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"156909","DOI":"10.1016\/j.phymed.2025.156909","article-title":"Discovery of a novel Mark4 antagonist from safflower to improve ischemic stroke by inhibiting microglial Nlrp3 inflammasome activation","volume":"144","author":"Gao","year":"2025","journal-title":"Phytomedicine"},{"key":"key20260925073129_b40-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"2015130","DOI":"10.1080\/20002297.2021.2015130","article-title":"Microtubule affinity regulating kinase 4 promoted activation of the NLRP3 inflammasome-mediated pyroptosis in periodontitis","volume":"14","author":"Wang","year":"2021","journal-title":"J Oral Microbiol"},{"key":"key20260925073129_b41-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"key20260925073129_b42-ol-32-5-15863","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:31:35Z","timestamp":1790310695000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15863","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}